Nureca Ltd (NURECA)
🎯 Key Takeaways
- Nureca Ltd is transitioning from a loss-making entity to a profitable, growth-oriented consumer healthcare platform with integrated manufacturing capabilities. The company has demonstrated consistent quarter-on-quarter revenue and margin expansion, supported by strategic investments in capacity and operational efficiency.
- Revenue grew 13.9% QoQ to ₹40 in Q1FY27.
- ⚠️ The company’s revenue is heavily reliant on domestic demand and regulatory approvals in the healthcare sector, exposing it to policy and pricing risks
📖 The Story
Nureca Ltd is transitioning from a loss-making entity to a profitable, growth-oriented consumer healthcare platform with integrated manufacturing capabilities. The company has demonstrated consistent quarter-on-quarter revenue and margin expansion, supported by strategic investments in capacity and operational efficiency. It is now in a phase of scalable, profitable growth, underpinned by a strong balance sheet and improving financial performance.
📰 What's Happening
In Q1 FY27, Nureca reported revenue of ₹40.3 crores, up 18% YoY and 14% QoQ, driven by strong gross margins and operating profitability. PAT rose to ₹3.1 crores from ₹0.9 crores YoY, with operating profit margin expanding to 8.7% from 7.3% QoQ. Management highlighted the merger with Nureca Technologies as a key strategic enabler and plans to expand manufacturing capacity in Punjab for medical devices and consumables to capture growing market demand.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 38 | 40 | 35 | 40 |
| Operating Profit | 3 | 3 | -6 | 3 |
| OPM % | 7.3% | 6.9% | -17.6% | 7.0% |
| Net Profit | 4 | 4 | -6 | 3 |
| EPS | ₹3.63 | ₹3.91 | ₹-6.45 | ₹3.21 |
Revenue has grown steadily over the past four quarters, from ₹35 crores in Q3 FY26 to ₹40.3 crores in Q1 FY27, with margins improving from negative 17.6% in Q3 FY26 to 7.0% in Q1 FY27. This turnaround reflects successful cost control and operational scaling, aligning with management’s focus on profitability and integration of the merged entity. The company is now generating sustainable operating profits and positive net income trends.
🔮 Management Outlook & What's Next
Management projects the addressable market for medical devices and consumables to grow to ₹5,203 crores by 2030 at a 9.9% CAGR, providing a clear runway for expansion. The company is investing in manufacturing capacity in Punjab to support this growth and has emphasized the integration of Nureca Technologies as central to its long-term strategy. No formal forward guidance on revenue or margins was provided, but the outlook is anchored in structural market growth and operational scalability.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 |
| Reserves | 184 | 184 | 189 | 171 |
| Borrowings | 5 | 5 | 5 | 1 |
| Total Liabilities | 215 | 210 | 225 | 196 |
| Fixed Assets | 7 | 7 | 13 | 14 |
| Investments | 4 | 1 | 8 | 1 |
| Total Assets | 215 | 210 | 225 | 196 |
The balance sheet shows stable equity at ₹10 crores with reserves growing from ₹171 crores to ₹189 crores, indicating retained earnings and profitability. Borrowings remain low and stable at ₹1–5 crores, reflecting minimal leverage. Total assets have grown from ₹210 crores to ₹225 crores, signaling asset base expansion in line with operational growth. The company is not capital-intensive in terms of debt, and asset growth is funded through internal accruals and reserves.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +3 |
| Investing | +14 |
| Financing | -20 |
| Net Cash Flow | -2 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 65.0% | 68.1% | 68.1% |
| FII | 0.1% | 0.3% | 0.1% |
| DII | 0.0% | 0.2% | 0.2% |
| Public | 33.0% | 28.8% | 29.1% |
| # Shareholders | 35,801 | 34,558 | 33,979 |
Promoter holding remains stable at 68.09%, with no signs of dilution. FII and DII ownership have slightly increased from 0.08% to 0.28% and 0.04% to 0.24% respectively over the past three quarters, suggesting growing institutional interest. The rise in the number of shareholders (from 35,801 to 33,979) may reflect retail participation, but the core ownership structure remains promoter-dominated and stable.
⚖️ Peer Comparison — E-Commerce/App based Aggregator
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| ETERNAL | 3.12 L Cr | 687.2 | 4.1% | 1.4% | 0.00 |
| PAYTM | 1.16 L Cr | 177.8 | 4.8% | 4.3% | 0.00 |
| NYKAA | 98,286 | 385.6 | 24.2% | 18.0% | 0.52 |
| POLICYBZR | 83,088 | 110.6 | 11.4% | 10.2% | 0.00 |
| NAUKRI | 81,111 | 50.6 | 6.2% | 5.0% | 0.00 |
| SWIGGY | 76,709 | — | -19.2% | -20.5% | 0.01 |
| URBANCO | 25,747 | — | -11.7% | -15.6% | 0.00 |
| PINELABS | 23,348 | 179.1 | 4.1% | 2.2% | 0.05 |
| TBOTEK | 18,226 | 67.8 | 17.0% | 17.1% | 0.42 |
| NAZARA | 14,243 | — | -1.3% | -1.5% | 0.03 |
⚠️ Risk Factors
1. The company’s revenue is heavily reliant on domestic demand and regulatory approvals in the healthcare sector, exposing it to policy and pricing risks. 2. Integration of Nureca Technologies carries execution risk, including cultural alignment and operational synergies. 3. Despite margin improvement, the company operates in a highly competitive and price-sensitive market with thin margins. 4. Foreign exchange volatility could impact imported raw materials or export-oriented segments, though not currently a primary focus.
📋 Recent Filings
-
🔴 Insider Trading 10 September 2026Ms. Smita Goyal, a promoter group member of Nureca Limited, acquired shares of the company on September 10, 2026, as required under SEBI's PIT Regulat...
-
🔴 Insider Trading 9 September 2026Ms. Smita Goyal, a promoter group member of Nureca Limited, acquired shares of the company on September 9, 2026, triggering mandatory disclosure under...
-
🔴 Insider Trading 29 August 2026Nureca Limited disclosed an insider share purchase by a designated person under SEBI's PIT Regulations, Regulation 7(2), filed manually on BSE and NSE...
-
🔴 Insider Trading 11 August 2026Nureca Limited disclosed an insider share purchase by a designated person under SEBI PIT Regulations, Regulation 7(2), which was not automatically ref...
-
🔴 Financial Results 21 July 2026Nureca reported Q1 FY27 revenue of **₹40.3 crores**, up 14% QoQ and 18% YoY, driven by strong gross margins and operating profitability. The company p...
-
🟡 Board Meeting 21 July 2026Nureca Limited announced the unaudited standalone and consolidated financial results for Q1 FY26-27 ended June 30, 2026, showing revenue of **₹423.14 ...
-
share transfer 15 July 2026Nureca Limited received a SEBI-mandated share transfer agent certificate for the quarter ended June 30, 2026, confirming all shareholders hold shares ...
-
🔴 annual report 3 July 2026Nureca Limited's FY26 annual report shows revenue growth of 34% to ₹1,469.93 crores, EBITDA up 68.94% to [amount context mismatch] crores, and PAT sur...
-
🔴 Insider Trading 3 July 2026Mr. Aryan Goyal, a promoter group member of Nureca Limited, disposed of equity shares via an off-market transfer under a family settlement agreement d...
-
🟡 Board Meeting 1 July 2026No summary available
🧠 Analyst's Read
Nureca is executing a clear turnaround narrative with consistent revenue growth, improving margins, and strategic capacity expansion. The key watchpoints are successful integration of the merger, scalability of the manufacturing expansion, and sustained margin resilience in a competitive healthcare market. Investors should monitor execution updates from the Punjab facility and any guidance on market share gains in the medical devices segment.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-13.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when NURECA files new disclosures
Track NURECA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track NURECA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd